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ABSTRACT
Among the bacteria of the HACEK group, Actinobacillus actinomycetemcomitans is the organism involved
most commonly in infective endocarditis. However, the epidemiological and clinical features speciﬁcally
associated with this species have not been evaluated adequately. Three patients with infective
endocarditis caused by A. actinomycetemcomitans seen at the Hospital La Timone (Marseille, France)
between 1994 and 2001 are reported. Of 99 cases in the literature, 75% of patients had previous heart
disease before infective endocarditis, the portal of entry of which was usually the oral cavity. Among the
total of 102 cases, 27 had prosthetic valves. Intermittent fever was observed in all cases, and weight loss
and peripheral signs of endocarditis were noteworthy in this study. Anaemia andmicroscopic haematuria
were frequently noted. The disease is insidious, with a mean duration of symptoms of 13 weeks before
diagnosis, as conﬁrmed by blood cultures incubated for > 5 days. The aortic valve is most commonly
involved, and echocardiographic ﬁndings were non-speciﬁc. Complications occurred in 63% of patients,
with emboli being the most common. The surgery rate was 23.5%. The overall mortality rate was 18%. Of
the cases, 76.5%were curedwith antibiotics alone, including a simple third-generation cephalosporin or a
combination of ampicillin and an aminoglycoside. An antibiotic therapy duration of at least 4 weeks is
recommended. Surgical therapy is usually required for haemodynamic reasons. Prophylaxis of
A. actinomycetemcomitans endocarditis relies on antibiotic therapy for all cardiac patients at risk before
dental procedures. Among 17 patients undergoing dental manipulations, only eight received amoxycillin
before the procedure, demonstrating that prophylaxis is far from being systematically prescribed. In
conclusion, A. actinomycetemcomitans endocarditis should be highly suspected in patients with previous
cardiac disease and for whom symptoms have evolved over a number of weeks or even months.
Keywords Actinobacillus, endocarditis
Accepted: 16 May 2003
Clin Microbiol Infect 2004; 10: 98–118
INTRODUCTION
Actinobacillus (Haemophilus) actinomycetemcomitans,
a small Gram-negative coccobacillus and fastidi-
ous microorganism, was ﬁrst described by Klinger
in 1912. The species was so named because, until
1964, it had been reported as being isolated
exclusively in cases of actinomycosis or actinomy-
cotic-like lesions. In 1953, Valle´e and Gaillard [1]
mentioned two isolations of a similar organism
from blood cultures of patients with endocarditis,
but no details were provided; however, in 1964, the
ﬁrst case of endocarditis caused by A. actinomyce-
temcomitanswas described by Mitchell and Gillep-
sie [2]. Since that ﬁrst description of the organism
as a sole agent of endocarditis, there have been 99
cases reported by authors from different countries.
In 1959, Heinrich and Pulverer demonstrated
that A. actinomycetemcomitans was a constituent of
the normal mouth ﬂora; indeed, it frequently
colonises the oropharynx, and thus it is commonly
found in human periodontal cultures. Its patho-
genic role in periodontitis—particularly localised
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juvenile periodontitis—is well established [3];
infection may be transmissible among individuals,
as suggested by the high frequency of positive
periodontal culture among family members of
patients with localised juvenile periodontitis [3].
A. actinomycetemcomitans is an unusual agent of
infective endocarditis (IE), and is grouped in the
HACEK group of bacteria, along with Haemophi-
lus inﬂuenzae, H. parainﬂuenzae, H. aphrophilus,
H. paraphrophilus, Cardiobacterium hominis, Eikenel-
la corrodens and Kingella kingae. All possess similar
traits: they are small Gram-negative bacteria, are
frequent colonisers of the oral cavity, are slow
growing, and have their growth enhanced by
enriched media and the presence of carbon
dioxide (although these bacteria are not phylo-
genically related). All HACEK microorganisms
produce similar clinical syndromes that are often
insidious. They cause 3% of all cases of IE [4],
and, among them, A. actinomycetemcomitans is the
most frequently involved. The species is easily
isolated, although it requires a prolonged incuba-
tion time; blood cultures are positive in 90% of
cases of A. actinomycetemcomitans infection when
incubated for longer than 8 days [4]. Patients with
endocarditis and a history of periodontal disease
or dental procedures, and for whom blood cul-
tures remain negative, might have infection
caused by A. actinomycetemcomitans (or one of
the HACEK group).
Previous studies [3–5] have found several
characteristics of IE caused by A. actinomycetem-
comitans. In this article, we report three addi-
tional cases of A. actinomycetemcomitans endocar-
ditis that were diagnosed in the laboratory of
La Timone (Marseille, France) according to the
diagnostic criteria from the Duke Endocarditis
Service, and review the epidemiological, clinical,
biological, echocardiographic and histological
features, treatment and outcome of these infre-
quently reported infections in the literature.
NEW CASE REPORTS
Case 1
A 48-year-old man with aortic and mitral valve
damage secondary to rheumatic heart disease had
undergone double valve replacement with a Saint
Jude prosthesis in 1991. The postoperative course
was uncomplicated. Three years later, the patient
was readmitted with a 2-month history of inter-
mittent fever, fatigue, chills and pains in the right
forearm and leg. He had a history of recent dental
manipulation, with amoxycillin given for prophy-
laxis. In January 1994, he was treated with
roxithromycin for sore throat and sinusitis diag-
nosed in general practice, but, despite remaining
febrile during antibiotic therapy, he did not see a
doctor again until his hospital admission at the
end of March 1994. An initial physical examina-
tion showed fever of 39 C and general weakness.
The cardiac examination revealed a grade 2 ⁄ 6
systolic murmur. There were no peripheral signs
of either endocarditis or splenomegaly. The white
blood cell (WBC) count and the platelet count
were normal. The patient’s haematocrit was low,
with an erythrocyte sedimentation rate of
30 mm ⁄h. C-reactive protein reached a concen-
tration of 45 mg ⁄L, and ﬁbrinogen reached a
concentration of 6 g ⁄L. Immune complexes were
detected. There was no microscopic haematuria.
Serum creatinine was elevated.
Abdominal computed tomography (CT) revea-
led a prominent homogeneous spleen, the chest
X-ray ﬁlm showed no abnormalities, and there
were dental caries on X-ray. A transthoracic
echocardiogram (TTE) was unremarkable, apart
from a grade 2 ⁄ 6 aortic insufﬁciency. Seven blood
cultures were drawn on the day of arrival, and
three grew A. actinomycetemcomitans on the same
day. The organism was sensitive to doxycycline,
gentamicin, oﬂoxacin and third-generation
cephalosporins, but showed intermediate sensi-
tivity to penicillin and erythromycin. On the third
day of hospitalisation, intravenous antibiotic ther-
apy was begun with ceftriaxone, 2 g ⁄day. The
patient became afebrile within 2 days. After
10 days of treatment, a head CT scan was carried
out because of right hemiplegia with aphasia, and
revealed a large left rolandic haemorrhage con-
sistent with a ruptured mycotic aneurysm.
After 42 days of intravenous antibiotic therapy,
the patient was well and remained afebrile. He
partly recovered from his neurological handicap
with relevant re-education.
Case 2
In January 1995, a 51-year-old man had begun
experiencing fever, 3 weeks after dental manipu-
lations without antibiotic prophylaxis. An initial
prescription of amoxycillin provided no improve-
ment, and the fever began to ﬂuctuate, with night
sweats and weakness. In February, the patient was
admitted to another hospital, but no diagnosis was
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obtained, and the patient was discharged on the
fourth day. He continued to complain of chills
and intermittent fever during the following
weeks, so was readmitted to hospital on March
17. His fever ranged between 38C and 39C in
the ﬁrst 7 days of hospitalisation. Physical exam-
ination revealed a systolic–diastolic murmur in
the aortic area, hepatomegaly and splenomegaly.
Osler’s node was found on the left little toe. There
was no clubbing, no splinter haemorrhage and no
Janeway lesion. Dental examination revealed per-
iodontal infection. The results of laboratory tests
on admission showed a normal WBC count, a
normal platelet count, and moderate anaemia.
The sedimentation rate was 100 mm ⁄h in the ﬁrst
hour, the C-reactive protein level was 102 mg ⁄L,
and the ﬁbrinogen level was 7.5 g ⁄L. Serum
creatinine and transaminases were normal, as
were a chest X-ray and abdominal and cerebral
scans. TTE showed a severe aortic valve regurgi-
tation with a 20-mm abscess localised at the base
of the aorta. All three blood cultures drawn on the
ﬁrst day yielded A. actinomycetemcomitans.
The patient was given amikacin 1 g ⁄day and
ceftriaxone 2 g ⁄day intravenously for 2 days;
amikacin was then replaced by rifampicin
1.5 g ⁄day, and he received 5 weeks of this com-
bination therapy. On 12 April, he underwent an
aortic valve replacement. Histological examina-
tion of the valve revealed ﬁbrosis and calciﬁca-
tions, with a small inﬂammatory area
characterised by ﬁbrin and lymphocytes. The
patient did well until June 2000, when a dysfunc-
tion of the bioprosthesis was noted, but without
surgical indication.
Case 3
In August 2000, a 45-year-old man, with a long
history of bicuspid aortic valve stenosis secon-
dary to rheumatic heart disease, complained of
fever with chills and fatigue. He had no history
of recent dental procedures. On admission in
November 2000, physical examination revealed
him to be chronically ill. His blood pressure
was 120 ⁄ 70 mmHg, his pulse was 96 beats ⁄min,
and his temperature reached 39.5C. Murmurs
of both aortic stenosis and regurgitation were
audible. Clubbing and Osler’s node on the
second ﬁnger of the left hand and on the little
right toe were observed. Laboratory studies
revealed normocytic normochromic anaemia of
9.7 g haemoglobin ⁄dL. The WBC count was
21 000 ⁄mm3, and the thrombocyte count was
324 000 ⁄mm3. The erythrocyte sedimentation rate
was 122 mm ⁄h, the C-reactive protein level was
184 mg ⁄L, and the ﬁbrinogen level was 8.5 g ⁄L.
Transaminases and serum creatinine were nor-
mal. Microscopic haematuria was noted. Rheu-
matoid factor and immune complexes were both
absent. No abnormality was found on cerebral,
thoracic and abdominal CT scans, and X-ray
investigations revealed a granuloma in tooth 27.
A TTE revealed an aortic valve vegetation of
2 cm, with an abscess hanging from the right
coronary valvula. On the second day of hospital-
isation, two of three blood cultures grew
A. actinomycetemcomitans. Intravenous antibiotic
therapy with cefotaxime (12 g ⁄day) and rifampi-
cin (600 mg every 12 h) was started. One month
later, the patient underwent aortic valve replace-
ment with drainage of the abscess and insertion of
a pacemaker because of a third-degree atrioven-
tricular block. Histological examination of the
valve showed a large vegetation covering the
valvular surface and signiﬁcant inﬂammatory
inﬁltration with numerous granulocytes. No
microorganisms were seen, but culture of the
removed valve yielded A. actinomycetemcomitans.
The patient did well during 6 weeks of treatment,
and dental procedures led to sterilisation of the
suspected source of infection.
REVIEW OF THE LITERATURE
This review is based on a MEDLINE search using
the Pubmed database with the following key-
words: infection or infective endocarditis due to
Actinobacillus actinomycetemcomitans. High-quality
case reports containing adequate information
were eligible for analysis. Pooled cases with
limited or summary ﬁndings were not included.
Our search had no time or language restrictions.
Among the 53 references found (99 cases), 35 were
written in English, eight in Spanish, ﬁve in
French, three in German, one in Hebrew, and
one in Portuguese. Moreover, all full references
that described human cases found since the ﬁrst
case description in 1964 were recorded.
A ﬁrst reading of all articles allowed establish-
ment of a formulary, in which all relevant data for
the study were collected (Fig. 1). This included
epidemiological features (risk factors, age, under-
lying conditions or pre-existing heart disease),
duration of symptoms before diagnosis, clinical
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Fig. 1. Form used to collect data on endocarditis caused by Actinobacillus actinomycetemcomitans. Other: native valve
damage, previous endocarditis, hypertrophic obstructive, cardiomyopathy. VSD: ventricular septal defect. RHD, rheumatic
heart disease; CHF, congestive heart failure; ALT, alanine aminotransferase.; PM, pace maker; RF, rheumatoid factor; CIC,
circulating immune-complexes. aNative valve damage, previous endocarditis, hypertrophic obstructive cardiomyopathy,
VSD.
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presentation, biological results, echocardiography
ﬁndings, histology, complications, treatment and
outcome. Data from the 102 cases were entered
into the Microsoft Access structured processing
package. With use of this program, a synoptic
table presenting features of each case was created
(Table 1) [6–54], and was used for analysing and
comparing data in order to highlight possible
speciﬁc characteristics of IE caused by A. actin-
omycetemcomitans.
REVIEW OF THE RESULTS
In total, 99 cases were analysed from reports in the
literature. The addition of the three newcases led to
a 102-case series. Among these cases, 73 patients
were male and 29 female (male ⁄ female ratio of
2.52). Themeanage of adult patientswas 46.8 years
(range 21–77 years). Three cases in children aged
7–10 years were encountered, of which two were
reported in an earlier review [47]. Age was not
speciﬁed for six patients. Fourteen (50%) female
patients contracted the infection between 50 and
70 years of age, and 37 (50%) of 73 men developed
endocarditis between 40 and 60 years of age.
Risk factors
Risk factors are summarised in Table 2. These
included underlying cardiopathy, previous val-
vular damage and surgery, and dental status.
Previous heart disease was noted in 76.5% of
infected patients. Among these, 23% had congen-
ital disease, 50% had rheumatic disease, 8% had a
bicuspid aortic valve, and one patient had a
pacemaker. Of these patients, 18% presented with
various associated diseases, including endocardi-
tis, Q fever, congestive heart failure, aneurysm of
the sinus of Valsalva, and mitral valve prolapse.
Among the infected patients, 35 had previously
known valvulopathy, and 27 had a prosthetic
valve, biological in 15 cases and mechanical in 12.
Oral infection is a likely source for some of
these cases, but others could originate from oral
hygiene procedures (brushing, ﬂossing) and mas-
tication [55,56]. In this review, 43 patients were
presumed to have a poor dental condition; 36
presented with carious teeth at the time of
diagnosis, and seven had parodontopathy. Sev-
enteen patients had undergone dental procedures
before infection. Only 47% received antibiotic
prophylaxis before and during these manipula-
tions, and penicillin or erythromycin was usually
prescribed.
Duration of symptoms before diagnosis
Of the 102 patients who developed A. actinomyce-
temcomitans endocarditis, adequate information
on the duration of symptoms was available for 75.
The time from the ﬁrst symptom to hospital admis-
sion ranged from 2 days to 60 weeks [57] (two
patients in whom endocarditis had begun several
months before diagnosis were excluded). The
mean duration of symptoms was 13 weeks (the
two patients cited above were excluded, plus one
who presented with acute high-grade fever of
2 days duration before hospital admission [7]).
Clinical and biological features of presentation
and diagnosis
Fever was present in 76 (97.4%) of 78 patients. Of
these, 70% were admitted to hospital with inter-
mittent fever. Weight changes were documented
for 45 patients. Of these, 30 (66.7%) lost weight.
A new or altered heart murmur was found in
57 (73%) of 78 patients. Twenty-one (27.6%) of
76 had hepatomegaly, 22 (29%) of 76 had spleno-
megaly, and ﬁve (6.6%) of 76 had both. Osler’s
nodes were found in 10% of patients (7 ⁄ 74), all of
Table 2. Attributable risk factors for 102 patients with
Actinobacillus actinomycetemcomitans endocarditis
Risk factor No. of cases
Underlying cardiopathy 78
Congenital 18
Bicuspid aortic valve 6
Rheumatic heart disease 39
Pacemaker 1
Othersa 14
Previous valve damage or surgery
Altered native valve 35
Prosthetic valve 27
Biological 15; aortic 8, mitral 7
Mechanical 12; aortic 8, mitral 4
Dental status
Dental disease 43
Carious teeth 36
Parodontopathy 7
Dental procedure 17
With antibiotics 8 ⁄ 17
aEndocarditis, aneurysm of the sinus of Valsalva, mitral
insufﬁciency (prolapse), Q fever, congestive heart failure.
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whom had these symptoms on ﬁrst examination.
Finally, 14 of 77 patients had a rash at the time of
diagnosis.
Laboratory ﬁndings revealed an elevated sedi-
mentation rate in 62 (98.4%) of 63 patients, and
mild or severe anaemia in 59 (88%) of 67 patients.
Leukocytosis was more frequent than leukopenia
(28 (45.2%) of 62 patients vs. two (3.2%) of 60).
Microscopic haematuria was found in 69.4%
(Table 3). Creatinine levels were elevated in
18 (22.8%) of 79 cases. Platelets, rheumatoid
factors, circulating immune complexes and liver
enzyme levels were not well-documented.
Anatomical site of A. actinomycetemcomitans
endocarditis
The anatomical site of the vegetations was deter-
mined in 75 patients, with the aortic valve being
the most commonly affected site (38 ⁄ 75; 50.7%).
The mitral valve alone was involved in 25 cases
(33.3%). Other sites included the tricuspid valve
(two patients), and in ten cases there were
vegetations on two or three valves: aortic and
mitral (seven patients), aortic and tricuspid (one
patient), aortic, mitral and tricuspid (one patient),
and mitral, tricuspid and pulmonary (one
patient).
Echocardiography
Echocardiography (Table 4) was introduced as a
diagnostic tool for A. actinomycetemcomitans endo-
carditis during the early 1980s, with only one
investigation being performed before 1975 [17]. In
total, 54 patients underwent echocardiography.
The distinction between transthoracic and trans-
oesophageal modes was often not speciﬁed.
An echocardiogram was normal for ﬁve cases
(9.2%), and vegetations were found in 30 patients
(55.5%), 19 of which were in the aortic area and
11 of which were on the mitral valve. A ring
abscess was present in three cases (5.5%), inclu-
ding the two cases from this study (both compli-
cating a bicuspid aortic valve), and a 38-year-old
man with a prosthetic aortic valve. In 17 patients
(32.5%), the valve was damaged or thickened,
and in ten (18.5%) patients, there was paravalvu-
lar leakage. Only one dehiscence of prosthesis
(1.9%) was described. In six (11.1%) cases, other
abnormalities were found, including rupture of
‘cordage’, ventricular defect, aneurysm of the
sinus of Valsalva, or perforated septal aneurysm.
Table 4. Echocardiographic characteristics in 54 cases of
Actinobacillus actinomycetemcomitans endocarditis
Characteristic No. (%)
Normal 5 (9.2)
Vegetation(s) 30 (55.5)
Abscess 3 (5.5)
Thickening 17 (31.5)
Paravalvular leakage 10 (18.5)
Prosthesis dehiscence 1 (1.9)
Othersa 6 (11.1)
aRupture of cordage, ventricular defect, aneurysm of the
sinus of Valsalva, ventricular septum defect.
Table 3. Pre- or post-treatment com-
plications and outcome in 102 cases
of Actinobacillus actinomycetemcomi-
tans endocarditis
Native
valve IE
Yes/No (%)
Prosthetic
valve IE
Yes/No (%)
Overall
rate
Yes/No (%)
Evolution unknown 23 ⁄ 52 (30.7) 1 ⁄ 26 (3.7) 24 ⁄ 78 (23.5)
No complication 17 ⁄ 58 (22.7) 12 ⁄ 15 (44.4) 29 ⁄ 49 (37)
Complication(s) 34 ⁄ 41 (45.3) 15 ⁄ 12 (55.5) 49 ⁄ 29 (63)
Embolia 17 ⁄ 58 (22.7) 6 ⁄ 21 (22.2) 23 ⁄ 55 (29.5)
CHF 14 ⁄ 61 (18.7) 7 ⁄ 20 (25.9) 21 ⁄ 57 (27)
Renal failureb 9 ⁄ 66 (12) 2 ⁄ 25 (7.4) 11 ⁄ 67 (14)
Cardiopathy worsenedc 2 ⁄ 73 (2.7) 7 ⁄ 20 (25.9) 9 ⁄ 69 (11.5)
Ruptured aneurysmd 3 ⁄ 72 (4) 1 ⁄ 26 (3.7) 4 ⁄ 74 (5)
Surgery rate 24 ⁄ 78 (23.5)
Mortality rate 18 ⁄ 84 (18)
aPeripheral (11) (retinal, splenic, limb), cerebral (10), renal (8), coronary (3),
pulmonary (1).
bVarious mechanisms: embolism, post-aminoglocoside, nephritis.
cWorsening of the pre-existing cardiopathy without cardiac heart failure (CHF).
dCerebral (3), femoral (1).
IE, infective endocarditis.
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Source of diagnosis
Seventy-eight patients had more than one blood
culture performed during their ﬁrst hospitalisa-
tion. In all cases, these cultures yielded A. actin-
omycetemcomitans (100% sensitivity). The time
taken for cultures to become positive was reported
for 54 cases. A mean delay of 7.1 days occurred,
with a range of 1–15 days. Cardiac vegetation
cultures were reported for only 19 patients, and
were positive in two cases. One of the patients
described in this study had a positive aortic
vegetation culture and positive PCR detection.
Endocarditis complications and recurrence
Complications were reported in 49 (63%) of
78 cases (Table 3). Emboli were the most common
complications observed (29.5%). Eleven of these
were peripheral (retinal, splenic or in a limb), ten
were cerebral, eight were renal, three were cor-
onary, and one was pulmonary. Congestive heart
failure was noted in 21 (27%) patients, renal
failure in 11 (14%), and four ruptures of mycotic
aneurysm (5%) were observed (three cerebral and
one femoral). Among the patients who experi-
enced embolism, seven of 23 died, and ﬁve cases
of congestive heart failure also did not survive.
No recurrence of A. actinomycetemcomitans endo-
carditis was reported.
When the information provided is considered
according to the type of IE—native or pros-
thetic—it can be seen that a prosthetic IE is more
likely to involve complications than a native one
(55.5% vs. 45.3%). Cardiac heart failure and
worsening of the pre-existing cardiopathy seem
to be more frequent with prosthetic IEs (25.9% vs.
18.7%). Embolism was equally prevalent in the
two types of IE (22.2% and 22.7%, respectively).
Treatment and outcome
All patients received antibiotic therapy, and 24
(23.5%) received surgical treatment that consisted
of a valve or a prosthesis replacement with or
without abscess drainage (Table 1). Antibiotic
treatment generally comprised a combination of
two, three or four antibiotics given intravenously
for a mean time of 5.8 weeks. The antibiotics
prescribed varied over time, with prescription of
penicillin and streptomycin until the beginning of
the 1980s (25 of 52 cases between 1964 and 1983),
and then ampicillin, often in association with an
aminoglycoside, between 1985 and 1990. Third-
generation cephalosporins became the drugs of
choice in the 1990s; among these, ceftriaxone was
prescribed most commonly. Twenty-four (23.5%)
patients underwent surgery because antibiotic
treatment failed or because of complications.
Congestive heart failure was a predominant
indication for surgery (13 cases), six patients had
deterioration of valve function, one had persistent
bacteraemia, and three underwent aortic valve
replacement because of perivalvular abscess (one
case presented conduction defects). No details of
the decision to operate were given for one patient.
The aortic valve was involved in 19 of 24 proce-
dures, and four of six patients with bicuspid
aortic valve disorders underwent surgery. Alto-
gether, 18 patients died as a direct result of
endocarditis (Table 3).
DISCUSSION
We have reported three cases of A. actinomyce-
temcomitans endocarditis encountered at our insti-
tution, and reviewed 99 other cases found in the
international literature. This review supports and
extends similar previously published studies,
thereby facilitating the identiﬁcation of A. actin-
omycetemcomitans endocarditis. This microorgan-
ism is a fastidious Gram-negative coccobacillus
that forms part of the normal oral ﬂora. However,
as an opportunistic pathogen, it is strongly asso-
ciated with periodontitis, especially juvenile per-
iodontitis, and it can cause disease manifestations
such as endocarditis, bactaeremia, and polymi-
crobial wound infections [4]. The bacteria may
gain entry to the vascular compartment via dental
infection, dental treatment procedures, or spon-
taneous random bactaeremias resulting from oral
hygiene procedures or mastication. This situation
is the most frequent and was described by
Guntheroth [55] in 1984 and by Roberts [56] in
1999; it is far more likely that bactaeremias
following everyday procedures (mastication, oral
hygiene) are the cause of bacterial endocarditis
than those following surgical procedures. More-
over, in 1998, Strom et al. [58] reported that
‘‘dental treatment does not seem to be a risk
factor for infective endocarditis’’. In this study, a
possible dental origin was found in 59% of cases.
Only 16.9% were related to dental procedures,
and 42.2% to dental disease. Dental caries were
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noted for most of the cases, whereas A. actin-
omycetemcomitans is seen only in periodontal
disease. However, periodontopathy is often la-
tent, combined with carious teeth, and it has often
been omitted in the cases reported. Carious teeth
suggest poor dental condition and also sponta-
neous random bactaeremias that may cause IE.
As noted in previous reviews and in cases of
endocarditis caused by other organisms, A. actin-
omycetemcomitans endocarditis occurs most com-
monly in men (two-thirds of the patients), and the
mean age of patients reported here was
46.8 years. A. actinomycetemcomitans preferentially
infects underlying cardiopathies. The most fre-
quent site of endocarditis is the aortic valve
(50.7% of cases), and the relative frequency of a
bicuspid aortic valve among the congenital con-
ditions before endocarditis should be noted. A
bicuspid aortic valve is reportedly the most
common site of congenital heart lesion. A recent
study by Lamas and Eykyn [24] found that, of
50 patients who presented with bicuspid aortic
valve endocarditis, all were male, with a mean
age of 39 years. Only 35% of them previously
knew that they had a heart condition. There was a
high incidence of serious complications such as
heart failure and periannular abcesses. Surgery
was required in 82% of cases. In our study, ﬁve
of six patients with bicuspid aortic valve endo-
carditis were male; two had cardiac heart failure,
and two had aortic root abcesses. Surgery was
performed on four of six patients.
A. actinomycetemcomitans endocarditis is a sub-
acute or chronic illness with a prolonged symp-
tomatic period before diagnosis, as shown by the
long median duration of this period in our study,
and the observation that diagnosis was made
during the acute phase in only a few cases. The
onset of disease is very insidious and intermittent.
Furthermore, changes in the intensity of the
symptoms experienced by patients increased the
difﬁculty of early diagnosis of the endocarditis.
Fever was present in almost all cases, but was so
capricious that examination of the patient did not
necessarily reveal an infection. As diagnosis is
often made after a long period of disease, physical
signs of chronic illness can develop, and it is not
surprising to notice that most of our patients
presented with weight loss, that liver and spleen
enlargement were seen in 28% and 29% of cases
respectively, and that Osler’s nodes occurred in
9.5% of cases. No biological abnormalities can be
associated speciﬁcally with A. actinomycetemcom-
itans as compared with other agents of endocar-
ditis, but microscopic haematuria, the signiﬁcance
of which remains unclear, seems to be quite
frequent (69.4%).
The fastidious growth requirements of
A. actinomycetemcomitans may lead to delay in
microbiological diagnosis. A previous review
reported that diagnosis was typically made
between days 6 and 30 [3]. In this study, the
mean duration of blood culture incubation before
detection of growth was 7.1 days. Only in a few
cases was diagnosis made in the ﬁrst 3 days, and
it still remains unusual. Blood cultures were the
main source of diagnosis. Culture of cardiac
vegetation appears to be insensitive, but molecu-
lar methods for detecting the microorganism on
the valve (such as PCR) may be practical alterna-
tives. In 1997, Goldenberger et al. [37] applied
broad-range bacterial PCR ampliﬁcation to 18
resected heart valves from patients with endocar-
ditis. For 11 patients, there was agreement with
culture-based ﬁndings, whereas in two cases,
molecular-based techniques yielded organisms
while cultures were negative. In our study, PCR
on a removed valve was used for only one
patient, but was positive for A. actinomycetemcom-
itans. In 2000, Millar et al. [21] described the
application of molecular-based techniques on
resected valves, and blood or other samples, and
their usefulness in diagnosis of the aetiological
agents in cases of culture-negative endocarditis.
The addition of these methods to the Duke criteria
as a major criterion was proposed [22]. Accord-
ingly, the authors suggested that these methods
should be performed in all cases of culture-
negative endocarditis where the patient has
already been identiﬁed as having either a deﬁnite
or possible diagnosis of IE by other criteria.
Vegetations were seen in > 50% of the patients,
and were characteristically large [4]. This size
possibly reﬂects the delayed diagnosis of cases.
TTE plays an important role in the diagnosis,
assessment and management of endocarditis.
Because of the relatively long duration of
infection before diagnosis in patients with
A. actinomycetemcomitans endocarditis, patients
are exposed to a greater risk of complications
than in acute endocarditis associated with
other infectious causes [4]. The complications
observed most commonly were emboli. Among
the other complications occurring in the series,
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cardiac heart failure and renal insufﬁciency were
remarkable, but did not inﬂuence the endocarditis
prognosis. One-third of the patients did not
experience any complication. Finally, A. actin-
omycetemcomitans endocarditis of either native or
prosthetic valves appears to be associated with a
relatively good prognosis, as 82% of patients
survived. This observation is probably associated
with the high antibiotic susceptibility of A. actin-
omycetemcomitans. b-Lactamase production has
never been noted in A. actinomycetemcomitans
strains. The threat of b-lactam antibiotic resistance
is currently not a problem with this microorgan-
ism [59]. Intravenous ampicillin sodium
(12 g ⁄ 24 h) with gentamicin sulphate (1 mg ⁄ kg
every 8 h) should thus be considered the treat-
ment of choice for A. actinomycetemcomitans endo-
carditis, and ampicillin can be expected to be
effective as endocarditis prophylaxis for perio-
dontitis patients harboring A. actinomycetemcomi-
tans [60]. According to the consensus of the
American Heart Association writing group
(1995), the duration of treatment should be
4 weeks for native valve infection and 6 weeks
for prosthetic valve endocarditis. More care
should be taken when treating endocarditis
caused by other HACEK bacteria generally,
because of b-lactamase production, and the
third-generation cephalosporins, particularly cef-
triaxone sodium administered 2 g once-daily
intravenously or intramuscularly, should be con-
sidered the drugs of choice. It was observed that
surgical treatment is often required as a result of
treatment failure, persistent infection, or compli-
cations such as congestive heart failure or sys-
temic emboli. Indications for surgical treatment of
HACEK endocarditis generally follow the recom-
mendations of the Endocarditis Working Group
of the International Society of Chemotherapy [14].
The HACEK group is responsible for 3% of
community-acquired cases of IE [4]. A. actin-
omycetemcomitans, with 102 cases found in the
literature, is the most commonly reported micro-
organism of the HACEK group in cases of
endocarditis. They may present more diagnostic
difﬁculty than other bacteria encountered more
frequently in endocarditis because of previous
use of antimicrobial agents, which is in part
responsible for culture-negative endocarditis, or
because these fastidious bacteria are demanding
in terms of culture media and duration of
incubation. However, each infectious agent of
the group demonstrates some unique character-
istics.
CONCLUSION
The clinical presentation of HACEK endocarditis
does not differ signiﬁcantly from one microor-
ganism to another, but there are some unique
indicators that could help direct physicians
towards the identity of the precise infectious
agent. In particular, A. actinomycetemcomitans
endocarditis should be suspected in patients with
underlying cardiopathy who present with a sub-
acute or chronic illness. Diagnosis is mainly based
on blood cultures. Ampicillin combined with
gentamicin for 4 weeks for native valve infection,
and for 6 weeks for prosthetic valve infection, is
the standard treatment. Surgical procedures fol-
low the recommendations of the Endocarditis
Working Group of the International Society of
Chemotherapy [14]. Antibiotic prophylaxis
should be followed for dental procedures, even
if spontaneous random bactaeremias resulting
from ‘everyday’ procedures are more likely to
lead to IE than are teeth extractions.
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